Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68(22 Suppl 3):S22-S31

Department of Neuroscience, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Neurology (Impact Factor: 8.29). 06/2007; 68(22 Suppl 3):S22-31; discussion S43-54. DOI: 10.1212/01.wnl.0000275229.13012.32
Source: PubMed


Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the CNS. Approximately 2 million people worldwide have MS, with females outnumbering males 2:1. Because of its high prevalence, MS is the leading cause of nontraumatic neurologic disability in young adults in the United States and Europe. Axon loss is the major cause of irreversible disability in patients with MS. Axon damage, including transection of the axon, begins early in MS and correlates with inflammatory activity. Several mechanisms lead to axon loss, including inflammatory secretions, loss of myelin-derived support, disruption of axonal ion concentrations, energy failure, and Ca(2+) accumulation. Therapeutic interventions directed toward each of these mechanisms need to be tested for their efficacy in enhancing axon survival and, ultimately, their ability to delay progression of neurologic disability in patients with MS.

Download full-text


Available from: Ranjan Dutta, Mar 24, 2015
  • Source
    • "We also showed that ACTH stimulated OPC proliferation and induced OL to elaborate larger and more dense membrane sheets (Benjamins et al., 2014). It is increasingly clear that damage to axons/neurons is important in the pathogenesis of MS in all stages of the disease (Ferguson et al., 1997; Trapp et al., 1998; Dutta and Trapp, 2007; Lassmann, 2013; Mahad et al., 2015). While some axonal and neuronal loss may result from changes in function in demyelinated axons (Dutta and Trapp, 2011; Criste et al., 2014), some damage and neuronal loss may be caused by direct effects of mediators of excitotoxicity and inflammation (Lisak et al., 2012; Lassmann, 2014a, 2014b). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with relapsing remitting multiple sclerosis (RRMS) are commonly treated with high doses of intravenous corticosteroids (CS). ACTH 1-39, a member of the melanocortin family, stimulates production of CS by the adrenals, but melanocortin receptors are also found in the central nervous system (CNS) and on immune cells. ACTH is produced within the CNS and may have direct protective effects on glia and neurons independent of CS. We previously reported that ACTH 1-39 protected oligodendroglia (OL) and their progenitors (OPC) from a panel of excitotoxic and inflammation-related agents. Neurons are the most vulnerable cells in the CNS. They are terminally differentiated, and sensitive to inflammatory and excitotoxic insults. For potential therapeutic protection of gray matter, it is important to investigate the direct effects of ACTH on neurons. Cultures highly enriched in neurons were isolated from 2-3 day old rat brain. After 4-7 days in culture, the neurons were treated for 24hours with selected toxic agents with or without ACTH 1-39. ACTH 1-39 protected neurons from death induced by staurosporine, glutamate, NMDA, AMPA, kainate, quinolinic acid, reactive oxygen species and, to a modest extent, from rapidly released NO, but did not protect against kynurenic acid or slowly released nitric oxide. Our results show that ACTH 1-39 protects neurons in vitro from several apoptotic, excitotoxic and inflammation-related insults. Copyright © 2015. Published by Elsevier Inc.
    Experimental Neurology 08/2015; 273. DOI:10.1016/j.expneurol.2015.08.012 · 4.70 Impact Factor
  • Source
    • "As far as myelin sheath is concerned, we have supposed that this aerobic metabolism supports the axonal energy demand [24]. This would be consistent with the hypothesis that myelin sheath plays an as yet unidentified trophic role [25] considering that myelin loss in demyelinating diseases leads to an axonal degeneration, the cause of the most severe symptoms in these pathologies [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative phosphorylation (OXPHOS) is the main source of ATP for the cell, but also a major source of Reactive Oxygen Species (ROS), which lead to oxidative stress. At present, mitochondria are considered the organelles responsible for the OXPHOS, but in the last years we have demonstrated that it can also occur outside the mitochondrion. Myelin sheath is able to conduct an aerobic metabolism, producing ATP that we have hypothesized is transferred to the axon, to support its energetic demand. In this work spectrophotometric, cytofluorimetric and luminometric analyses were employed to investigate the oxidative stress production in isolated myelin, as far as its respiratory activity is concerned. We have evaluated the levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), markers of lipid peroxidation, as well as of hydrogen peroxide (H2O2), marker of ROS production. To assess the presence of endogenous antioxidant systems, superoxide dismutase, catalase and glutathione peroxidase activities were assayed. The effect of certain uncoupling or antioxidant molecules on oxidative stress in myelin was also investigated. We report that isolated myelin produces high levels of MDA, 4-HNE and H2O2, likely through the pathway composed by Complex I - III - IV, but it also contains active superoxide dismutase, catalase and glutathione peroxidase, as antioxidant defense. Uncoupling compounds or Complex I inhibitors increases oxidative stress, while antioxidant compounds limit ROS generation. Data may shed new light on the role of myelin sheath in physiology and pathology. In particular, it can be presumed that the axonal degeneration associated with myelin loss in demyelinating diseases is related to oxidative stress caused by impaired OXPHOS.
    Free Radical Research 05/2015; 49(9):1-36. DOI:10.3109/10715762.2015.1050962 · 2.98 Impact Factor
  • Source
    • "rosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) (Delisle and Carpenter, 1984; Hori and Carpenter, 1994; Takahashi et al., 1997; Trapp et al., 1998; Dickson et al., 1999; Mattila et al., 1999; Swann et al., 2000; Goel et al., 2003; Pavlidis et al., 2003; Saito et al., 2003; Dutta and Trapp, 2007 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Microglia are macrophage-like resident immune cells that contribute to the maintenance of homeostasis in the central nervous system (CNS). Abnormal activation of microglia can cause damage in the CNS, and accumulation of activated microglia is a characteristic pathological observation in neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases. Activated microglia secrete high levels of glutamate, which damages CNS cells and has been implicated as a major cause of neurodegeneration in these conditions. Glutamate-receptor blockers and microglia inhibitors (e.g., minocycline) have been examined as therapeutic candidates for several neurodegenerative diseases; however, these compounds exerted little therapeutic benefit because they either perturbed physiological glutamate signals or suppressed the actions of protective microglia. The ideal therapeutic approach would hamper the deleterious roles of activated microglia without diminishing their protective effects. We recently found that abnormally activated microglia secrete glutamate via gap-junction hemichannels on the cell surface. Moreover, administration of gap-junction inhibitors significantly suppressed excessive microglial glutamate release and improved disease symptoms in animal models of neurologic conditions such as stroke, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Recent evidence also suggests that neuronal and glial communication via gap junctions amplifies neuroinflammation and neurodegeneration. Elucidation of the precise pathologic roles of gap junctions and hemichannels may lead to a novel therapeutic strategies that can slow and halt the progression of neurodegenerative diseases.
    Frontiers in Cellular Neuroscience 09/2014; 8(189). DOI:10.3389/fncel.2014.00189 · 4.29 Impact Factor
Show more